Protein tyrosine phosphatases: emerging role in cancer therapy resistance

被引:3
作者
Zhao, Min [1 ,2 ]
Shuai, Wen [1 ,2 ]
Su, Zehao [1 ,2 ,3 ]
Xu, Ping [4 ]
Wang, Aoxue [1 ,2 ]
Sun, Qiu [1 ,2 ]
Wang, Guan [1 ,2 ]
机构
[1] Sichuan Univ, West China Hosp, Natl Clin Res Ctr Geriatr, Innovat Ctr Nursing Res,Nursing Key Lab Sichuan Pr, Chengdu 610041, Sichuan, Peoples R China
[2] Sichuan Univ, West China Hosp, Natl Clin Res Ctr Geriatr, State Key Lab Biotherapy,West China Sch Nursing, Chengdu 610041, Sichuan, Peoples R China
[3] Sichuan Univ, West China Biomed Big Data Ctr, Med X Ctr Informat, Chengdu, Sichuan, Peoples R China
[4] Zigong Fourth Peoples Hosp, Emergency Dept, Chengdu, Sichuan, Peoples R China
基金
中国国家自然科学基金;
关键词
cancer treatment; combination therapy; drug resistance; protein tyrosine phosphatase; MISMATCH REPAIR; ALLOSTERIC INHIBITION; CLINICAL-RESPONSE; IFN-GAMMA; SHP2; PATHWAY; IMMUNOTHERAPY; DEFICIENCY; MECHANISMS;
D O I
10.1002/cac2.12548
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundTyrosine phosphorylation of intracellular proteins is a post-translational modification that plays a regulatory role in signal transduction during cellular events. Dephosphorylation of signal transduction proteins caused by protein tyrosine phosphatases (PTPs) contributed their role as a convergent node to mediate cross-talk between signaling pathways. In the context of cancer, PTP-mediated pathways have been identified as signaling hubs that enabled cancer cells to mitigate stress induced by clinical therapy. This is achieved by the promotion of constitutive activation of growth-stimulatory signaling pathways or modulation of the immune-suppressive tumor microenvironment. Preclinical evidences suggested that anticancer drugs will release their greatest therapeutic potency when combined with PTP inhibitors, reversing drug resistance that was responsible for clinical failures during cancer therapy.Areas coveredThis review aimed to elaborate recent insights that supported the involvement of PTP-mediated pathways in the development of resistance to targeted therapy and immune-checkpoint therapy.Expert opinionThis review proposed the notion of PTP inhibition in anticancer combination therapy as a potential strategy in clinic to achieve long-term tumor regression. Ongoing clinical trials are currently underway to assess the safety and efficacy of combination therapy in advanced-stage tumors.
引用
收藏
页码:637 / 653
页数:17
相关论文
共 99 条
[1]   Mechanism-based treatment of cancer with immune checkpoint inhibitor therapies [J].
Abdou, Yara ;
Pandey, Manu ;
Sarma, Maithreyi ;
Shah, Shrunjal ;
Baron, Jeffrey ;
Ernstoff, Marc S. .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 86 (09) :1690-1702
[2]   Strategies to Address Chimeric Antigen Receptor Tonic Signaling [J].
Ajina, Adam ;
Maher, John .
MOLECULAR CANCER THERAPEUTICS, 2018, 17 (09) :1795-1815
[3]   Protein tyrosine phosphatase receptor type C (PTPRC or CD45) [J].
Al Barashdi, Maryam Ahmed ;
Ali, Ahlam ;
McMullin, Mary Frances ;
Mills, Ken .
JOURNAL OF CLINICAL PATHOLOGY, 2021, 74 (09) :548-552
[4]  
Amgen (U.S), 2019, IDENTIFIER NCT041858
[5]   IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade [J].
Ayers, Mark ;
Lunceford, Jared ;
Nebozhyn, Michael ;
Murphy, Erin ;
Loboda, Andrey ;
Kaufman, David R. ;
Albright, Andrew ;
Cheng, Jonathan D. ;
Kang, S. Peter ;
Shankaran, Veena ;
Piha-Paul, Sarina A. ;
Yearley, Jennifer ;
Seiwert, Tanguy Y. ;
Ribas, Antoni ;
McClanahan, Terrill K. .
JOURNAL OF CLINICAL INVESTIGATION, 2017, 127 (08) :2930-2940
[6]   Ptpn11/Shp2 Acts as a Tumor Suppressor in Hepatocellular Carcinogenesis [J].
Bard-Chapeau, Emilie A. ;
Li, Shuangwei ;
Ding, Jin ;
Zhang, Sharon S. ;
Zhu, Helen H. ;
Princen, Frederic ;
Fang, Diane D. ;
Han, Tao ;
Bailly-Maitre, Beatrice ;
Poli, Valeria ;
Varki, Nissi M. ;
Wang, Hongyang ;
Feng, Gen-Sheng .
CANCER CELL, 2011, 19 (05) :629-639
[7]   Phosphorylation of PD-1-Y248 is a marker of PD-1-mediated inhibitory function in human T cells [J].
Bardhan, Kankana ;
Aksoylar, Halil-Ibrahim ;
Le Bourgeois, Thibault ;
Strauss, Laura ;
Weaver, Jessica D. ;
Delcuze, Bethany ;
Charest, Alain ;
Patsoukis, Nikolaos ;
Boussiotis, Vassiliki A. .
SCIENTIFIC REPORTS, 2019, 9 (1)
[8]   Interferon target-gene expression and epigenomic signatures in health and disease [J].
Barrat, Franck J. ;
Crow, Mary K. ;
Ivashkiv, Lionel B. .
NATURE IMMUNOLOGY, 2019, 20 (12) :1574-1583
[9]   The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity [J].
Baumgartner, Christina K. ;
Ebrahimi-Nik, Hakimeh ;
Iracheta-Vellve, Arvin ;
Hamel, Keith M. ;
Olander, Kira E. ;
Davis, Thomas G. R. ;
McGuire, Kathleen A. ;
Halvorsen, Geoff T. ;
Avila, Omar I. ;
Patel, Chirag H. ;
Kim, Sarah Y. ;
Kammula, Ashwin V. ;
Muscato, Audrey J. ;
Halliwill, Kyle ;
Geda, Prasanthi ;
Klinge, Kelly L. ;
Xiong, Zhaoming ;
Duggan, Ryan ;
Mu, Liang ;
Yeary, Mitchell D. ;
Patti, James C. ;
Balon, Tyler M. ;
Mathew, Rebecca ;
Backus, Carey ;
Kennedy, Domenick E. ;
Chen, Angeline ;
Longenecker, Kenton ;
Klahn, Joseph T. ;
Hrusch, Cara L. ;
Krishnan, Navasona ;
Hutchins, Charles W. ;
Dunning, Jax P. ;
Bulic, Marinka ;
Tiwari, Payal ;
Colvin, Kayla J. ;
Chuong, Cun Lan ;
Kohnle, Ian C. ;
Rees, Matthew G. ;
Boghossian, Andrew ;
Ronan, Melissa ;
Roth, Jennifer A. ;
Wu, Meng-Ju ;
Suermondt, Juliette S. M. T. ;
Knudsen, Nelson H. ;
Cheruiyot, Collins K. ;
Sen, Debattama R. ;
Griffin, Gabriel K. ;
Golub, Todd R. ;
El-Bardeesy, Nabeel ;
Decker, Joshua H. .
NATURE, 2023, 622 (7984) :850-+
[10]   Molecular Pathways: Targeting Protein Tyrosine Phosphatases in Cancer [J].
Bollu, Lakshmi Reddy ;
Mazumdar, Abhijit ;
Savage, Michelle I. ;
Brown, Powel H. .
CLINICAL CANCER RESEARCH, 2017, 23 (09) :2136-2142